Effects of melatonin on behavioral dopaminergic supersensitivity

Life Sciences

Volumn 72, Issue 26, 2003, Pages 3003-3015

  Abílio, Vanessa C ^a   Vera Jr , João A R ^a   Ferreira, Leonardo S M ^a   Duarte, Carlo R M ^a   Martins, César R ^a   Torres Leite, Danila ^a   Ribeiro, Rosana De A ^a   Frussa Filho, Roberto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Behavior; Dopamine; Dopaminergic supersensitivity; Melatonin; Rat

Indexed keywords

HALOPERIDOL; MELATONIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG WITHDRAWAL; LONG TERM CARE; MALE; NONHUMAN; OPEN FIELD BEHAVIOR; PLASTICITY; RAT; STEREOTYPY; SUPERSENSITIVITY;

EID: 0037449055     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00231-5     Document Type: Article

References (64)

1. Abílio V.C., Freitas F.M., Dolnikoff M.S., Castrucci A.M.L., Frussa-Filho R. Effects of continuous exposure to light on behavioral dopaminergic supersensitivity. Biological Psychiatry. 45(12):1999;1622-1629.
2. Abílio V.C., Vera J.A.R. Jr., Ferreira L.S.M., Duarte C.R.M., Carvalho R.C., Grassl C., Martins C.R., Torres-Leite D., Bignotto M., Tufik S., Ribeiro R. de A., Frussa-Filho R. Effects of melatonin on orofacial movements in rats. Psychopharmacology. 161(4):2002;340-347.
3. Ahlenius S., Hillegaart V., Thorell G., Magnusson O., Fowler C.J. Suppression of exploratory locomotor activity and increase in dopamine turnover following the application of cis-flupenthixol into limbic projection areas of the rat striatum. Brain Research. 402(1):1987;131-138.
4. Aldegunde M., Miquez I., Veira J. Effects of pinealectomy on regional brain serotonin. International Journal of Neuroscience. 26(1-2):1985;9-13.
5. Al-Ghoul W.M., Herman M.D., Dubocovich M.L. Melatonin receptor subtype expression in human cerebellum. Neuroreport. 9(18):1998;4063-4068.
6. Al-Khatib I.M.H., Dökmeci I., Fujiwara M. Differential role of nucleus accumbens and caudate-putamen in mediating the effect of nomifensine and methamphetamine on ambulation and rearing of rats in the open-field test. Japanese Journal of Pharmacology. 67(1):1995;69-77.
7. Bernardi M.M., Palermo-Neto J. Effects of abrupt and gradual withdrawal from long-term haloperidol treatment on open-field behavior of rats. Psychopharmacology. 65(3):1979;247-250.
8. Bradbury A.J., Kelly M.E., Smith J.A. Melatonin action in the mid brain can regulate forebrain dopamine function both behaviourally and biochemically. Brown G.M., Wainwright S.D. The Pineal Gland: Neuroendocrine Aspects. 1985;327-332 Pergamon Press, Oxford.
9. Brainard G.C., Richardson B.A., King T.S., Matthews S.A., Reiter R.J. The suppression of pineal melatonin content and N-acetyltransferase activity by different light irradiances in the Syrian Hamster: a dose-response relationship. Endocrinology. 113(1):1983;293-296.
10. Broadhurst P.L. Experiments in psychogenetics. Eisink H.J. Experiments in Personality. 1960;Routledge and Kegan Paul, London.
11. Burt D.R., Creese I., Snyder S.H. Antischizophrenic drugs: chronic treatment elevates dopaminergic receptor in brain. Science. 196(4287):1977;326-327.
12. Casey D.E. Tardive dyskinesia-Pathophysiology. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation in Progress. 1995;1497-1502 Raven Press Ltd. New York.
13. Chouinard G., Jones B.D. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacological characteristics. American Journal of Psychiatry. 137(1):1980;16-21.
14. Chouinard G., Jones B.D., Annable L. Neuroleptic-induced supersensitivity psychosis. American Journal of Psychiatry. 135(11):1978;1409-1410.
15. Coloma F., Niles L.P. Melatonin enhancement of [3H]GABA and [3H]Muscimol binding in rat brain. Biochemical Pharmacology. 37(7):1988;1271-1274.
16. Creese I., Iversen S.D. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Research. 83(3):1975;419-436.
17. Drew E., Barrett P., Mercer J.G., Moar K.M., Canet E., Delagrange P., Morgan P.J. Localization of the melatonin-related receptor in the rodent brain and peripheral tissues. Journal of Neuroendocrinology. 13(5):2001;453-458.
18. Ebadi M., Srinivasan S.K. Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacological Reviews. 47(4):1995;575-604.
19. Ernst A.M. Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologia. 10(4):1967;316-323.
20. Felício L.F., Naselo A.G., Palermo-Neto J. Dopaminergic supersensitivity after long term bromopride treatment. Physiology and Behavior. 41(5):1987;433-437.
21. Flaherty A.W., Graybiel A.M. Anatomy of the basal ganglia. Marsden C.D., Fahn S. Movements Disorders Volume 3. 1994;2-27 Butterworth-Heineman, Oxford.
22. Fleminger S., Rupniak N.M.J., Hall M.D., Jenner P., Marsden C.D. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not increases in D-1 receptors. Biochemical Pharmacology. 32(19):1983;2921-2927.
23. Frussa-Filho R., Palermo-Neto J. Effects of single and long-term metoclopramide administration on open-field and stereotyped behavior of rats. European Journal of Pharmacology. 149(3):1988;323-329.
24. Frussa-Filho R., Palermo-Neto J. Effects of single and long-term administration of sulpiride on open-field and stereotyped behavior of rats. Brazilian Journal of Medical and Biological Research. 23(5):1990;463-472.
25. Jackson D.M., Anden N-E., Dahlström A. A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat brain. Psychopharmacologia. 45(2):1975;139-149.
26. Kapur S., Remington G.R. Serotonin-dopamine interactions and its relevance to schizophrenia. American Journal of Psychiatry. 153(4):1996;466-476.
27. Kelly P.H., Seviour P.W., Iversen S.D. Amphetamine and apomorphine responses in the rat following 6-OHDA lesion of the nucleus accumbens, septi and corpus striatum. Brain Research. 94(3):1975;507-522.
28. Klawans H.L. The pharmacology of extrapyramidal movement disorders. Cohen M.M. Monographs in Neural Science. 1973;1-37 Karger, Basel.
29. Koop N., Claustrat B., Tappaz M. Evidence for the presence of melatonin in the human brain. Neuroscience Letters. 19(3):1980;237-242.
30. Korsgaard S., Gerlach J., Christensson E. Behavioral aspects of serotonin-dopamine interaction in the monkey. European Journal of Pharmacology. 118(3):1985;245-252.
31. Latimer P.R. Tardive dyskinesia: a review. Canadian Journal of Psychiatry. 40(7 Suppl. 2):1995;49S-54S.
32. Laudon M., Nir I., Zisapel N. Melatonin receptors in discrete brain areas of the male rats. Impact of aging on density and on circadian rhythmicity. Neuroendocrinology. 48(6):1988;577-583.
33. LeDuc P.A., Mitteman G. Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations. Psychopharmacology. 110(4):1993;427-436.
34. Lewy A.J., Wehr T.A., Goodwin F.K., Newsome D.A., Markey S.P. Light supresses melatonin secretion in humans. Science. 210(4475):1980;1267-1269.
35. McIntyre I.M., Norman T.R., Burrows G.D., Armstrong S.M. Human melatonin response to light at different times of the night. Psychoneuroendocrinology. 14(3):1989;187-193.
36. Monteleone P., Esposito G., La Rocca A., Maj M. Does bright light suppress nocturnal melatonin secretion more in women than in men? Journal of Neural Transmission. 102(1):1995;75-80.
37. Moore R.Y., Klein D.C. Visual pathways and the central neural control of a circadian rhythm in pineal serotonin N-acetyltransferase. Brain Research. 71(1):1974;17-33.
38. Moss L.E., Neppe V.M., Drevets W.C. Buspirone in the treatment of tardive dyskinesia. Journal of Clinical Psychopharmacology. 13(3):1993;204-209.
39. Muller P., Seeman P. Dopaminergic supersensitivity after neuroleptics: time course and specificity. Psychopharmacology. 60(1):1978;1-11.
40. Palermo-Neto J. Supersensitivity, drug withdrawal, and open-field behavior. Psychopharmacology Bulletins. 18(4):1982;11-12.
41. Palermo-Neto J, Frussa-Filho R. Behavioural models of tardive dyskinesia in rodents: a chronological review. In: Bolis CL, Licino J, editors. Dopaminergic system: its evolution from biology to clinical aspects. Switzerland: AIREN International Association for Research and Training in Neurosciences and World Health Organization; 2001. p. 61-81.
42. Panke E.S., Rollag M.D., Reiter R.J. Pineal melatonin concentration in the Syrian Hamster. Endocrinology. 104(1):1979;194-197.
43. Parent A., Hazrati L. Functional anatomy f the basal ganglia. I. The cortico-basal-ganglia-thalamo cortical loop. Brain Research Reviews. 20(1):1995;91-127.
44. Piketty V. Absence of sexual dimorphism in pars tuberallis [125I]-melatonin binding sites of lambs slaughtered in June and October. Journal of Pineal Research. 30(1):2001;50-55.
45. Queiroz C.M.T., Frussa-Filho R. Effects of buspirone on dopaminergic supersensitivity. Life Sciences. 61(4):1997;371-382.
46. Queiroz C.M.T., Frussa-Filho R. Effects of buspirone on an animal model of tardive dyskinesia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 23(8):1999;1405-1418.
47. Raghavendra V., Naidu P.S., Kulkarni S.K. Reversal of reserpine-induced vacuous chewing movements in rats by melatonin, involvement of peripheral benzodiazepine receptors. Brain Research. 904(1):2001;149-152.
48. Rao M.L., Miller-Oerlinghausen B., Mackert A., Stieglitz R.D., Strebel B., Volz H.P. The influence of phototherapy on serotonin and melatonin in non-seasonal depression. Pharmacopsychiatry. 23(3):1990;155-158.
49. Reid M., Herrera-Marschitz M., Ungersted U. Effects of intranigral substance P and neurokinin A on striatal dopamine release-II. Interactions with bicuculine and naloxone. Neuroscience. 36(3):1990;659-667.
50. Reiter R.J. Action spectra, dose-dependent relationships and temporal aspects of light's effects on the pineal gland. Annals of the New York Academy of Sciences. 453:1985;215-230.
51. Reubi J.-C., Iversen L.L., Jessell T.M. Dopamine selectively increases 3H-GABA release from slices of rat substantia nigra. Nature. 268(5621):1977;652-654.
52. Roberts J.E. Visible light induced changes in the immune response through an eye-brain mechanism photoneuroimmunology. Journal of Photochemistry and Photobiology. B, Biology. 29(1):1995;3-15.
53. Rudeen P.K., Reiter R.J. Pineal N-acetyltransferase activity in hamsters maintained in shortened light cycles. Journal of Endocrinological Investigation. 2(1):1979;19-23.
54. Sandyk R., Consroe P., Iacono R.P. L-Tryptophan in drug-induced movement disorder with insomnia. New England Journal of Medicine. 314(19):1986;1257.
55. Sasaki T., Kennedy J.L., Nobrega J.N. Localized changes in GABA receptor-gated chloride channel in rat brain after long-term haloperidol: relation to vacuous chewing movements. Synapse. 25(1):1997;73-79.
56. Setler P., Sarau H., McKenzie G. Differential attenuation of some effects of haloperidol in rats given scopolamine. European Journal of Pharmacology. 39(1):1976;117-126.
57. A and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesia in rats. Experimental Neurology. 127(1):1994;62-69.
58. Tenn C.C., Niles L.P. Central-type benzodiazepine receptors mediate the antidopaminergic effect of clonazepam and melatonin in 6-hydroxydopamine lesioned rats: Involvement of a GABAergic mechanism. Journal of Pharmacology and Experimental Therapeutics. 274(1):1995;84-89.
59. Tenn C.C., Niles L.P. Mechanisms underlying the antidopaminergic effect of clonazepam and melatonin in striatum. Neuropharmacology. 36(11-12):1997;1659-1663.
60. Tufik S. Increased responsiveness to apomorphine after REM sleep deprivation: supersensitivity of dopamine receptors or increase in dopamine turnover? Journal of Pharmacy and Pharmacology. 33(11):1981;732-738.
61. Vital M.A.B.F., Frussa-Filho R., Palermo-Neto J. Effects of monosialoganglioside GM1 on dopaminergic supersensitivity. Life Sciences. 56(26):1995;2299-2307.
62. Vital M.A.B.F., Flório J.C., Frussa-Filho R., De Lucia R., Tufik S., Palermo-Neto J. Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover. Life Sciences. 62(13):1998;1161-1169.
63. Willis G.L., Armstrong S.M. A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiology and Behavior. 66(5):1999;785-795.
64. Zisapel N., Nir I., Laudon M. Circadia variations in melatonin-binding sites in discrete areas of the male rat brain. FEBS Letters. 232(1):1988;172-176.